Genzyme Corporation (GENZ) Release: U.S. Prescribing Information For Thyrogen Revised To Include Use Of Wider Range Of Radioiodine In Patients
3/27/2014 10:11:50 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced the Food and Drug Administration (FDA) approved revised prescribing information for the use of Thyrogen® (thyrotropin alfa for injection) to widen the dose range of radioiodine (RAI) when used for thyroid remnant ablation. Thyrogen is used before radioiodine treatment to enhance uptake of the radiotracer and allows patients to start and continue taking their thyroid hormone replacement therapy thus avoiding the untoward effects associated with hypothyroidism. Previously the amount of radioiodine was fixed at 100 mCi, whereas physicians may now select a dose from the range of 30-100 mCi.
Help employers find you! Check out all the jobs and post your resume.
comments powered by